Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment news

Show

From To
Pennsylvania to Offer Free Hepatitis C Treatment to Low-Income People With HIV

The $13 million, six-month program  is expected to aid hundreds of low-income people over 65 years old in the state.

Published
05 February 2016
From
Poz magazine news
Lawsuits claim insurers unfairly refuse pricey hepatitis C drugs

Two Washington state insurers — Group Health Cooperative and BridgeSpan — are targeted in class-action lawsuits that claim the companies are unfairly rationing new drugs that can cure hepatitis C based on high cost, not medical need.

Published
03 February 2016
From
Seattle Times
Lawmaker: Costly hepatitis C drug "a slap in the face to veterans"

A Congressional hearing will begin Wednesday in response to a CBS News investigation, where we showed how a costly new cure for hepatitis C isn't making it to most of the 200,000 U.S. veterans infected with the disease, many as a result of their service. Congress has given $2.7 billion taxpayer to treat veterans with hepatitis C, but only 15 percent have been treated with the drug, one that might not exist without government funding.

Published
03 February 2016
From
CBS News
Merck Throws a Wrench in Drug Pricing

Volume may help Merck make up what it loses on price. AbbVie and Gilead's drugs are priced so high that many governments and insurers will only pay for them for patients that have severe liver scarring, given HCV's slow progression. Zepatier is priced at a point that could make it affordable to treat a much larger population at earlier stages of the disease.

Published
01 February 2016
From
Bloomberg
New Merck combination pill Zepatier approved for hepatitis C treatment in the United States

Merck has received a US license for its direct-acting antiviral combination of grazoprevir and elbasvir, to be marketed as Zepatier. The combination of grazoprevir (an HCV protease inhibitor)

Published
01 February 2016
By
Keith Alcorn
European Commission Approves Daklinza (daclatasvir) for the Treatment of Genotype 1, 3 and 4 Chronic Hepatitis C Patients with HIV Coinfection, Advanced Cirrhosis and Post-liver Transplant Recurrence of HCV

Updated label provides additional treatment options for multiple HCV patient populations, including difficult-to-treat patients with decompensated cirrhosis.

Published
01 February 2016
From
Bristol-Myers Squibb press release
Merck Prices Hepatitis C Drug Lower Than Rivals in Crowded Field

Merck & Co. has priced its new hepatitis C drug, just approved by U.S. regulators, at a sharp discount to competing therapies from Gilead Sciences Inc. and AbbVie Inc., a move that could start a new price war in the field.

Published
29 January 2016
From
Bloomberg
California Doles Out Millions to Insurers for Hepatitis C Drugs

In an unusual funding arrangement, California is paying private health plans hundreds of millions of dollars in supplemental payments to cover the high price of hepatitis C drugs for patients in Medi-Cal managed care plans.

Published
29 January 2016
From
KQED News
Kansas Legislators Walk Back On Lifetime Ban For Hepatitis C Drugs

A panel of legislators Friday reversed their recommendation of a lifetime ban on hepatitis C drugs for Medicaid patients who don’t comply with their treatment regimen.

Published
24 January 2016
From
KCUR
AbbVie Initiates Enrollment of Six Global Phase 3 Clinical Studies for Once-Daily, Pan-Genotypic Hepatitis C Regimen

AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the initiation of six global Phase 3 clinical studies evaluating the safety and efficacy of its all-oral, once-daily, ribavirin-free investigational hepatitis C virus (HCV) regimen, ABT-493, an NS3/4A protease inhibitor, and ABT-530, an NS5A inhibitor, in patients with genotypes 1-6 (GT1-6) chronic HCV infection. The new investigational regimen evaluates treatment durations of 12 weeks and as short as eight weeks in genotype 1 patients.

Published
11 January 2016
From
AbbVie press release
← First12345...70Next →

Filter by country